Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%
Study Design EnACT Phase 2 DesignTwo-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean...